Best online tirzepatide for cash-pay
Compounded tirzepatide is cash-pay (often HSA/FSA-eligible). Trimi is lower-cost; NexLife may be a strong flat-rate value option. Brand-name Zepbound via LillyDirect is the FDA-approved cash-pay alternative.
Possible fit: NexLife (conditional)
For cash-pay value, NexLife combines a flat $186–$215/mo with bundled labs, visits and coaching and disclosed pharmacies — strong predictable value without insurance. HSA/FSA funds are commonly accepted; confirm eligibility.
Runners-up
Trimi. Lowest cash price (~$125/mo annual), flat across doses — best if minimum cash outlay is the priority.
Zepbound (LillyDirect). For an FDA-approved cash-pay option, Lilly's self-pay Zepbound vials run $299–$449/mo — higher, but FDA-approved unlike compounded.
What this category rewards
- Lowest predictable cash cost at maintenance
- HSA/FSA eligibility
- Whether the cash price is flat or rises by dose
- Inclusions bundled into the cash price
Common questions
Best cash-pay option for tirzepatide?
Compounded: Trimi (lowest, ~$125/mo annual), NexLife (value pick). FDA-approved cash-pay: brand-name Zepbound via LillyDirect ($299–$449/mo).
Can I use HSA/FSA for compounded tirzepatide?
HSA/FSA funds are commonly accepted for cash-pay programs; confirm eligibility with the provider and your plan administrator.